Stephen Liu: Phase Ib study of naporafenib with rineterkib or trametinib in NSCLC

Stephen Liu shared a post on X about a recent paper by David Planchard et al. published in Lung Cancer Journal.

“A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer”

Authors: David Planchard, Jürgen Wolf, Benjamin Solomon, Michele Moschetta, Christophe Dooms et al.

“Phase Ib study Lung Cancer Journal of the pan-RAF inhibitor naporafenib (LXH254) with either the ERK1/2 inhibitor rineterkib (LTT462) or the MEK1/2 inhibitor trametinib. In NSCLC, while safe and reductions in DUSP6 mRNA were observed, minimal activity.”

Source: Stephen Liu/X

More posts featuring Stephen Liu on oncodaily.com

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.

Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.